Status:
ACTIVE_NOT_RECRUITING
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
Lead Sponsor:
Qiu Ye
Collaborating Sponsors:
Guangzhou Medical University
Conditions:
Mucormycosis
Eligibility:
All Genders
Brief Summary
Background: Mucormycosis is a serious but rare fungal infection that requires rapid and effective treatment. The two main antifungal medicines used are amphotericin B and isavuconazole. However, more...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of mucormycosis based on histopathology, culture, or typical radiographic findings in accordance with established guidelines.
- Received primary antifungal treatment for mucormycosis with either amphotericin B (any formulation) or isavuconazole for at least 48 hours.
- Had at least one follow-up assessment after initiation of antifungal therapy to evaluate treatment response.
- Medical records from the participating hospitals are sufficiently complete for data extraction regarding treatment and outcomes.
Exclusion
- Patients who were not treated with amphotericin B or isavuconazole; and patients who did not have mucormycosis.
Key Trial Info
Start Date :
May 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 25 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07191756
Start Date
May 15 2025
End Date
September 25 2025
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangxi Medical University
Nanning, Guangxi, China